## References

1. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126:770–782.

2. Weinshenker BG, Bass GP, Rice J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133–146.

3. Weinshenker BG. Natural History of Multiple Sclerosis. Ann Neurol 1994;36:S6–S11.

4. Runmarker B, Andersen O. Prognostic factors in multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117–134.

5. Brex PA, Ciccarelli O, Jonathon I, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158–164.

6. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation within clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 1993;116: 135–146.

7. O’Riordan JJ, Thompson AJ, Kingsley DPE, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain 1998;121:495–503.

8. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon-beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343: 898–904.

9. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 2001;357:1576–1582.

10. Tintoré M, Rovira A, Rio J, et al. Optic neuritis between syndromes and myelitis: early conversion to multiple sclerosis. Med Clin (Barc) 1999;112:693–694.

11. Tintoré M, Rovira A, Rio J, et al. New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 2003;60:27–30.

12. Frohman EM, Goodin DS, Calabresi PA, et al. The utility of MRI in suspected MS. Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 2003;61:602–611.

13. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–127.

14. Stevenson VL, Archer T, Miller DH. Acute nasal syndrome: comparison of different MRI criteria used to predict conversion to clinically definite multiple sclerosis. J Neurol Neurosurg Psychiatry 1999;67:897–902.

15. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059–2069.

16. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research proposals. Ann Neurol 1983;13:227–231.

17. Tintoré M, Rovira A, Martínez MJ, et al. Isolated demyelinating syndromes: comparison of different MRI criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol 2000;21:702–706.

18. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992;27:581–588.

19. Rio J, Nos C, Rovira A, et al. The development of multiple sclerosis following an isolated episode of optic neuritis. Magnetic resonance study. Med Clin (Barc) 1997;109:370–372.

20. Rodriguez M, Siva A, Cross SA, et al. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 1995;45:244–250.

21. Miller DH, Ormerod IEC, McDonald WI, et al. The early risk of multiple sclerosis after optic neuritis. J Neurol Neurosurg Psychiatry 1988;51:1569–1571.

22. Söderström M, Ya-Ping J, Hillert J, Link H. Optic neuritis. Prognosis for multiple sclerosis from MRI, CSF and HLA findings. Neurology 1998;50:708–714.

23. Jacobs LD, Kaba SE, Miller CM, et al. Correlation of clinical, MRI and CSF findings in optic neuritis. Ann Neurol 1997;41: 392–398.